CHENNAI: Abl Biotechnologies Ltd on Thursday said it has signed a MoU with Christian Medical College, Vellore, for joint research in several areas in management of various diseases prevalent in Indian sub-continent.
"This MoU signals the beginning of an initiative that will bring together technological competence, research expertise and clinical acumen to accelerate the discovery of novel drugs targets and therapeutic approaches," K O Issac, Abl Chairman told reporters here today.
He also said Invia Health, a division of the company launched last year, would be expanding operations to Kerala, Andhra Pradesh, Karnataka and Orissa in August and September this year.
P S Ganeshan, President of the company said Abl would be launching Glimod M, Glysense and Eunerv G this year.
"Small volume parenterals will also launch in the anti-infective, anti-inflammatory and G I health segment".
"This MoU signals the beginning of an initiative that will bring together technological competence, research expertise and clinical acumen to accelerate the discovery of novel drugs targets and therapeutic approaches," K O Issac, Abl Chairman told reporters here today.
He also said Invia Health, a division of the company launched last year, would be expanding operations to Kerala, Andhra Pradesh, Karnataka and Orissa in August and September this year.
P S Ganeshan, President of the company said Abl would be launching Glimod M, Glysense and Eunerv G this year.
"Small volume parenterals will also launch in the anti-infective, anti-inflammatory and G I health segment".